Pfizer Recognized by Carbon Disclosure Project for Carbon Performance

NEW YORK--()--Pfizer (NYSE: PFE) announced that it has been commended by the Carbon Disclosure Project (CDP) for the actions it is taking to reduce emissions and mitigate the risks of climate change. For the first time, CDP named Pfizer to its Carbon Performance Leadership Index (CPLI), which highlights those companies within the FTSE Global Equity Index Series (Global 500) and the S&P 500 Index that have demonstrated a strong approach to climate strategy and emissions reduction in their CDP responses.

This year, Pfizer is ranked number two in the health care sector by the CDP for its carbon performance in the U.S. in the S&P 500, and number three in the health care sector in the Global 500.

“With more than 4,500 companies globally responding to CDP’s 2012 questionnaire, the fact that Pfizer falls within the top 10 percent of all responding companies in both the Global 500 and the S&P 500 Indices is something we are especially proud of,” says Tony Maddaluna, President, Pfizer Global Supply. “Since establishing our second greenhouse gas reduction goal in 2008, the company has completed more than 1,500 energy conservation and utility projects across the Pfizer enterprise. These efforts involved the implementation of energy- efficient technologies, the use of renewable technologies, and manufacturing improvements that have allowed us to reduce the energy consumed in all areas of our operations, from drug discovery and development through delivery to customers.”

Pfizer met its first greenhouse gas reduction goal in 2007 and is in the process of designing its third public goal.

Paul Simpson, chief executive officer of CDP, commented, “Companies in the Carbon Performance Leadership Index are demonstrating a clear commitment to manage their greenhouse gas emissions and take action on climate change. Organizations which work to reduce their emissions and integrate climate change issues into their business strategies have the potential for cost savings, revenue generating opportunities and, ultimately, a more resilient future.”

The Global 500 and S&P 500 reports, including names of companies featured in the CPLI and the methodology used, can be found at www.cdproject.net.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com. Find out more about Pfizer’s commitment to environmental sustainability at pfizer.com/ehs.

About CDP

The Carbon Disclosure Project (CDP) is an international, not-for-profit organization providing the only global system for companies and cities to measure, disclose, manage and share vital environmental information. CDP harnesses the power of market forces, including 655 institutional investors with assets of US$78 trillion, to collect information from companies on their greenhouse gas emissions and assessment of climate change and water risk and opportunity. CDP now holds the largest collection globally of primary climate change and water data and puts these insights at the heart of strategic business, investment and policy decisions. Please visit http://www.cdproject.net to find out more.

Contacts

Media:
Grace Ann Arnold, 845-602-4768
GraceAnn.Arnold@Pfizer.com

Contacts

Media:
Grace Ann Arnold, 845-602-4768
GraceAnn.Arnold@Pfizer.com